Latest Breaking News On - Primon lara jr - Page 1 : comparemela.com

Bone Biomarkers Predict Survival in Hormone-Sensitive Prostate Cancer

The findings can be used in patient counseling. Research confirms the clinical benefit of assessing bone biomarkers in hormone-sensitive prostate cancer.

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

High-Risk Renal Cell Carcinoma Patients Benefit from Everolimus

Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus: Clinical trial

Cabozantinib most effective treatment for metastatic papillary kidney cancer

 E-Mail IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more  Credit: City of Hope In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in